We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
126
Passage Bio
PASG
$15.8M
$153K 0.03%
+19,530
New +$202K
INO icon
127
CALL
Inovio Pharmaceuticals
INO
$92.1M
$131K 0.02%
75,200
-24,800
-25% -$40.8K
TLPH icon
128
Talphera
TLPH
$70.1M
$115K 0.02%
153,563
+16,640
+12% +$15.1K
RCKT icon
129
Rocket Pharmaceuticals
RCKT
$372M
$109K 0.02%
+30,579
New +$122K
MNPR icon
130
Monopar Therapeutics
MNPR
$727M
$89.3K 0.02%
+1,630
New +$98.5K
LYEL icon
131
PUT
Lyell Immunopharma
LYEL
$340M
$82.2K 0.01%
4,100
+300
+8% +$7.01K
VTGN icon
132
VistaGen Therapeutics
VTGN
$9.85M
$60.3K 0.01%
105,428
+5,428
+5% +$3.3K
RNA
133
Atrium Therapeutics
RNA
$208M
$33.6K 0.01%
+2,512
New +$35.3K
CUE icon
134
Cue Biopharma
CUE
$117M
$30.3K 0.01%
+4,400
New +$41.1K
ENTX icon
135
Entera Bio
ENTX
$98.6M
$25.8K ﹤0.01%
+23,260
New +$32.6K
PRTC
136
DELISTED
PureTech Health
PRTC
$11.3K ﹤0.01%
7,924
+482
+6% +$8.37K
IOVA icon
137
PUT
Iovance Biotherapeutics
IOVA
$2.08B
$10.2K ﹤0.01%
+2,900
New +$9.28K
ATYR
138
PUT
aTyr Pharma
ATYR
$50.6M
$9.75K ﹤0.01%
12,500
+700
+6% +$591
ELVN icon
139
Enliven Therapeutics
ELVN
$3.63B
$9.6K ﹤0.01%
+245
New +$6.79K
ATYR
140
CALL
aTyr Pharma
ATYR
$50.6M
$9.52K ﹤0.01%
12,200
-3,300
-21% -$2.79K
KOD icon
141
CALL
Kodiak Sciences
KOD
$2.58B
$7.62K ﹤0.01%
200
-29,400
-99% -$760K
SEPN
142
Septerna Inc
SEPN
$1.42B
$4.85K ﹤0.01%
+202
New +$5.31K
JBIO
143
PUT
Jade Biosciences
JBIO
$1.25B
$2.93K ﹤0.01%
1,046
– –
ABUS icon
144
CALL
Arbutus Biopharma
ABUS
$936M
– –
-548,600
Closed -$2.64M
ALNY icon
145
Alnylam Pharmaceuticals
ALNY
$37.8B
– –
-5,341
Closed -$2.12M
ALT icon
146
CALL
Altimmune
ALT
$554M
– –
-491,800
Closed -$1.78M
ANIP icon
147
ANI Pharmaceuticals
ANIP
$1.86B
– –
-53,354
Closed -$4.21M
APLT
148
CALL
DELISTED
Applied Therapeutics
APLT
– –
-20,200
Closed -$2.02K
AQST icon
149
CALL
Aquestive Therapeutics
AQST
$494M
– –
-211,100
Closed -$1.36M
AQST icon
150
PUT
Aquestive Therapeutics
AQST
$494M
– –
-337,700
Closed -$2.18M
4 5
6
7 8

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.